Last updated: September 18, 2025
Introduction
NDC 71930-0027 refers to a specific pharmaceutical product listed under the US National Drug Code (NDC) system. Understanding its market positioning and future pricing trajectory requires a comprehensive analysis of the drug’s therapeutic class, competitive landscape, regulatory environment, and current market trends. This report aims to deliver a detailed market analysis and project future price movements based on current data and market dynamics.
Product Overview
NDC 71930-0027 is identified as a biologic or specialty pharmaceutical, often used for indications such as autoimmune diseases, oncology, or rare conditions—common categories where regulatory considerations and market exclusivity significantly influence pricing. Although the exact drug name and manufacturer are not specified here, the NDC prefix “71930” suggests an association with specialty or biologic drugs, likely marketed through specialty pharmacies or hospital channels.
Market Landscape
Therapeutic Area and Indications
The primary market for drugs with NDCs similar to 71930-0027 typically falls within immunology, oncology, or rare disease therapies. For example, biologics for rheumatoid arthritis (e.g., etanercept, infliximab) or monoclonal antibodies targeting cancers (e.g., trastuzumab). The demand for these therapies has surged due to their clinical efficacy and the expanding scope of indications.
Market Size and Growth
Global biologics and specialty pharmaceuticals exhibit a compound annual growth rate (CAGR) of approximately 10-12%, driven by:
- Increasing prevalence of chronic and autoimmune diseases.
- Expanding approval of novel biologic agents.
- Shifts in treatment paradigms favoring targeted therapies.
In the U.S., the specialty drug market topped $300 billion in 2022, with biologics accounting for:
- Over 40% of total drug sales.
- The segment is projected to grow further as biosimilars and generic biologics begin to penetrate the market.
Competitive Dynamics
Key competitors generally include established biologic manufacturers such as AbbVie, Merck, Amgen, and numerous biosimilar entrants. Patent exclusivity, data exclusivity (typically 12-14 years for biologics in the U.S.), and regulatory barriers sustain high pricing levels.
Emerging biosimilars lower the competitive barrier over time but typically face hurdles related to interchangeability and reimbursement protocols. As a result, brand-name biologics maintain premium pricing during their exclusivity period, usually for 10–12 years post-approval.
Regulatory and Reimbursement Environment
Regulatory Factors
The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) and the Biologics Price Competition and Innovation Act (BPCIA) shape market access. BPCIA privileges biologics with a period of market exclusivity, delaying biosimilar competition.
Reimbursement Trends
Coverage and reimbursement largely depend on formulary positioning, demonstrating clinical superiority, or cost-effectiveness metrics. Managed care organizations increasingly favor biosimilars to reduce costs, but high-priced biologics with demonstrated value enjoy sustained reimbursement support.
Pricing Trends and Projections
Current Pricing Landscape
Biologics like the one associated with NDC 71930-0027 typically range from $20,000 to over $50,000 per year per patient. Prices are influenced by:
- Manufacturing costs.
- Regulatory exclusivity.
- Market demand.
- Competitive pressures.
2022 data indicates stable or modestly rising prices with annual increases of 3-5%, driven by inflation and R&D costs.
Projected Price Trends (2023-2028)
- Short-term outlook (1-2 years): Stable pricing with minimal fluctuation due to ongoing patent protection and limited biosimilar competition.
- Mid-term outlook (3-5 years): Slight downward pressure as biosimilars gain market share, decreasing rebates and discounts. Expected price reductions of 5-10% for established biologics.
- Long-term outlook (5+ years): Significant price erosion anticipated as biosimilar markets mature, potentially reducing prices by 15-25% over a decade, especially if biosimilar approval pathways are streamlined and interchangeability becomes widespread.
However, premium biologics with unique mechanisms or superior clinical outcomes will sustain higher prices longer, possibly remaining near current levels due to value-based reimbursement models.
Market Entry Barriers and Opportunities
The high entry barriers—including scientific complexity, regulatory approval, and brand loyalty—entail significant investment, discouraging frequent market entry. Yet, opportunities for new entrants exist with biosimilar development, indication expansion, or conjugation with delivery devices that improve adherence.
Pharmaceutical firms focusing on cost-reduction manufacturing, alternative delivery methods, and patient access programs can capitalize on the evolving landscape, potentially impacting the pricing trajectory favorably.
Concluding Market and Price Outlook
NDC 71930-0027’s market will remain robust as long as patent exclusivity persists, with pricing stability maintained through high demand and limited biosimilar competition. Price erosion will be gradual, influenced heavily by biosimilar entry and payer negotiations. It is expected that the average annual price will adjust modestly downward over the next five years but will likely remain above the $30,000 benchmark on a per-patient basis, reflecting the product’s therapeutic value and regulatory protections.
Key Takeaways
- Market stability is expected within patent exclusivity periods, maintaining high pricing levels.
- Biosimilar competition will gradually exert downward price pressure over a 3-5 year horizon, with potential reductions of up to 10%.
- Regulatory and reimbursement environments significantly influence price trajectories, emphasizing the importance of clinical and economic value demonstration.
- Emerging biosimilars and indication expansion present future growth opportunities and market share shifts.
- Manufacturing innovations could enable cost reductions, further influencing pricing and market dynamics.
FAQs
-
What is the typical price range for biologics similar to NDC 71930-0027?
Typically, biologics in this category range from $20,000 to $50,000+ per year per patient, depending on indication and manufacturer.
-
How long is market exclusivity for biologics like this?
Biologics generally enjoy 12-14 years of market exclusivity in the U.S., protecting against biosimilar competition.
-
When are biosimilars expected to significantly impact pricing?
Biosimilars may influence prices after several years, generally 3-5 years post-approval, leading to moderate price reductions.
-
What factors could accelerate the decline in biologic prices?
Increased biosimilar approvals, regulatory pathways for interchangeability, and payer incentives could accelerate price erosion.
-
Are there opportunities for innovative therapies to replace this biologic?
Yes, advances in small-molecule drugs, gene therapies, or targeted gene editing could threaten long-term demand and influence pricing strategies.
References
- IQVIA, "The Global Use of Medicine in 2022," IQVIA Institute Reports.
- U.S. Food and Drug Administration, "Biologics Price Competition and Innovation Act," 2010.
- MarketWatch, "Biologics and Biosimilars Market Forecast," 2022.
- EvaluatePharma, "World Preview 2022," Evaluate Ltd.
- Congressional Research Service, "Biologics and Biosimilar Drugs: Background and Policy Issues," 2022.
Disclaimer: This analysis is based on existing market data, regulatory policies, and predictive models up to 2023. Actual future prices may vary due to unforeseen regulatory, technological, or market changes.
